Drugs / SOLNERSTOTUG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05864144 | May 2023 → Jun 2027 expected | breast cancer, cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma +14 | Sensei Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOLNERSTOTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068295 ↗ |
| Known as | SNS-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05864144 ↗ |
| Modality | Monoclonal antibody | “SNS-101, a novel anti VISTA IgG1 monoclonal antibody” NCT05864144 ↗ |
| Route | Intravenous | “SNS-101 IV every 21 days.” NCT05864144 ↗ |